JNJ-4804 shows superior results in treating refractory ulcerative colitis and Crohn's disease, advancing to Phase 3 trials.

Johnson & Johnson's investigational co-antibody therapy JNJ-4804 demonstrated higher clinical remission and endoscopic response rates compared to golimumab and guselkumab in patients with moderately to severely active ulcerative colitis and Crohn's disease who failed two or more systemic therapies. Data from Phase 2b DUET studies showed meaningful improvements at Week 48, especially in highly refractory patients, addressing a critical unmet need in inflammatory bowel disease treatment. JNJ-4804 targets both IL-23 and TNF pathways, offering a synergistic approach. Based on these results, Johnson & Johnson plans to initiate Phase 3 trials for both conditions.